Advertisement
The Body: The Complete HIV/AIDS Resource Follow Us Follow Us on Facebook Follow Us on Twitter
Professionals >> Visit The Body PROThe Body en Espanol
  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

U.S. News

FDA Approves Bristol-Myers's New Hepatitis Drug

March 30, 2005

On Tuesday, the Food and Drug Administration approved Bristol-Myers's Baraclude (entecavir), an oral drug for treatment of chronic hepatitis B. An FDA advisory panel, which unanimously endorsed the approval, found a potential risk of tumors was not significant enough to outweigh Baraclude's benefits. The drug was put on fast track review after regulators found it addressed a serious unmet need.

Back to other news for March 30, 2005

Adapted from:
New York Times
03.30.05; Stephanie Saul

  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

This article was provided by U.S. Centers for Disease Control and Prevention. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update. Visit the CDC's website to find out more about their activities, publications and services.
 

 

Advertisement